Gulf War Syndrome Clinical Trial
— NACOfficial title:
Mechanisms of Oxidative Stress During N-Acetyl Cysteine (NAC) Supplementation in Veterans With Gulf War Illness (GWI)
This mechanistic study will test if NAC affects chronic oxidative stress and depletion of antioxidants in GWI participants. Blood specimen collection and neuroimaging will be used to determine whether NAC affects serum glutathione (GSH) concentration and oxidative stress in the CNS when compared to placebo.
Status | Recruiting |
Enrollment | 170 |
Est. completion date | September 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 47 Years to 70 Years |
Eligibility | Inclusion Criteria: - 47 to 70 years - Served in the Gulf War Theater for any period between August 1990 and July 1991. - Meets modified Kansas case definition criteria for Gulf War Illness. The modified Kansas definition includes the following: 1. Allowance of normal illness of aging, such as hypertension and diabetes, if the conditions are treated and are in demonstrable stable and normal ranges at the time of screening and assessment. 2. Allowance of stable comorbid conditions such as Post Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and mild Traumatic Brain Injury (mTBI) that have not required hospitalization in the 2 years prior to recruitment. Severe TBI is excluded. - Able to provide written consent to the study - Agrees to participate in follow-up visits. Exclusion Criteria: - Self-report of current treated or untreated major depression with psychotic or melancholic features (as determined by self-report and Hamilton Depression Inventory (Ham-D)), schizophrenia, bipolar disorder, delusional disorders, dementias of any type, or a history of central nervous system (CNS) disorders that may affect cognitive function (e.g., epilepsy, stroke, brain tumor, multiple sclerosis, Parkinson's Disease, Alzheimer's disease), or alcoholism or drug abuse - Severe claustrophobia or serious difficulty being in an MRI scanner or other enclosed space (MRS substudy only) - Presence of ferrous implanted medical devices or metal fragments or objects that are embedded under the skin (MRS substudy only) - Current heavy alcohol or tobacco use (self-report). Alcohol consumption not to exceed approximately 15 drinks per week (with a drink defined as 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) and tobacco use not to exceed 20 cigarettes (or equivalent) per day. - Chronic active infections such as HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) (self-report or antibody titer) - Renal disease (self-report or laboratory results: renal insufficiency with serum creatinine > 2.0 mg/dL) - Liver disease (self-report or laboratory results: hepatic insufficiency (bilirubin >2.5mg/dL or transaminases > 3 times the upper limits of normal) - Uncontrolled diabetes (HgbA1c > 7.5) without adequate medical care. Individuals with HgbA1c > 7.5 will be reviewed and judged by the PI or delegate; if potential participant has adequate medical care to manage diabetes, enrollment is allowed; otherwise HgbA1c > 7.5 is exclusionary - Diagnosed vascular disease (including congestive heart failure) - Diagnosed bleeding disorders or use of blood-thinning medications - Receipt of stavudine or didanosine for more than 7 days within 30 days prior to screening - Currently have exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity - Are scheduled for a surgery during the period of study participation or had surgery within 6 weeks prior to screening - Pregnant (women only) Prohibited Concomitant or Prior Therapies - Currently on dialysis - Previous or current receipt of any antiviral medication, such as pegylated interferon, ribavirin, entecavir, tenofovir, or didanosine for more than 7 days within 30 days prior to screening - Participating in another interventional (including social-behavioral therapy) clinical trial of an investigational therapy within 6 weeks prior to consent, or planning to participate in another interventional clinical trial of an investigational therapy during the course of this study - Any herbal medicine within 30 days prior to consent and screening blood draw |
Country | Name | City | State |
---|---|---|---|
United States | Boston University Medical School | Boston | Massachusetts |
United States | RTI International | Durham | North Carolina |
United States | VA New Jersey Health Care System War Related Illness and Injury Study Center | East Orange | New Jersey |
United States | Nova Southeastern University | Fort Lauderdale | Florida |
United States | Michael E. DeBakey VA Medical Center | Houston | Texas |
United States | Weill Cornell Medical College | New York | New York |
United States | VA Palo Alto Health Care System War Related Illness and Injury Study Center | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
Nova Southeastern University | Boston University, RTI International, Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess glutathione levels | Change in glutathione levels after NAC supplementation compared to placebo in participants with gulf war illness (GWI) | Baseline to 8 weeks | |
Secondary | Change in glutathione levels | Measure the change of brain glutathione levels with magnetic resonance spectroscopy (MRS) in a subset of both arms of study at baseline and 8 weeks. | Baseline to 8 Weeks | |
Secondary | Change in number of participants with treatment-related adverse events | Change in number of participants with treatment-related adverse events from baseline to 16 weeks during the intervention period as assessed by a safety questionnaire. | Baseline to 16 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00129454 -
Telemedicine Treatment for Veterans With Gulf War Illness
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT04182659 -
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|
N/A | |
Completed |
NCT03342482 -
Glutamate Neuro-Excitotoxicity in GWI
|
N/A | |
Completed |
NCT01264471 -
Mechanisms of Mitochondrial Defects in Gulf War Syndrome
|
N/A | |
Terminated |
NCT03547869 -
Transcranial Direct Current Stimulation for Pain Treatment in Gulf War Illness.
|
N/A | |
Recruiting |
NCT05675878 -
Confirmation of Diet as a Treatment for Gulf War Illness
|
Phase 3 | |
Recruiting |
NCT05736146 -
Validating Gulf War Illness Blood Biomarkers
|
||
Completed |
NCT03560830 -
START & STOPP in GWI
|
||
Recruiting |
NCT05355272 -
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
|
Phase 2 | |
Terminated |
NCT04712071 -
Ketamine in Veterans With Gulf War Illness
|
Early Phase 1 | |
Completed |
NCT03030794 -
Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS
|
N/A | |
Completed |
NCT04638998 -
Assessing Neuroinflammation in GWI Using MRS
|
||
Completed |
NCT02804828 -
Mitochondrial Cocktail for Gulf War Illness
|
N/A | |
Recruiting |
NCT02848417 -
Glutathione vs. Curcumin Clinical Trial
|
Phase 1/Phase 2 | |
Recruiting |
NCT00956150 -
Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex
|
Phase 1 | |
Completed |
NCT00018707 -
Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress
|
N/A | |
Not yet recruiting |
NCT05992311 -
Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
|
Phase 1 |